Ristova

Prescription Biologic (Anti-CD20)

Rituximab Injection (Biosimilar)

Manufacturer: Hetero / Roche

Description

Ristova is a biosimilar rituximab — an anti-CD20 monoclonal antibody that depletes B lymphocytes. Used in dermatology for severe, refractory pemphigus vulgaris and pemphigus foliaceus. Has transformed the management of pemphigus, a life-threatening autoimmune blistering disease.

Active Compounds

No tracked compounds

Indications

  • Pemphigus vulgaris (moderate-to-severe)
  • Pemphigus foliaceus
  • Refractory bullous pemphigoid

Dosage

1000mg IV infusion on day 0 and day 14. Repeat cycle at 6 months if needed. Premedicate with methylprednisolone, diphenhydramine, and paracetamol.

Formulations

IV infusion concentrate

Full Ingredient List

  • Rituximab
  • Sodium Citrate
  • Polysorbate 80
  • Sodium Chloride
  • Water for Injection

Side Effects

  • Infusion reactions (fever, chills, rigors)
  • Prolonged B-cell depletion
  • Increased serious infection risk
  • Progressive multifocal leukoencephalopathy (very rare)
  • Hepatitis B reactivation

Warnings

  • Screen for hepatitis B before starting — risk of reactivation
  • Screen for tuberculosis
  • Premedication mandatory to reduce infusion reactions
  • Monitor immunoglobulin levels
  • Avoid live vaccines
  • Must be administered in hospital/infusion centre